DCPS considering splitting certain health classes by gender
>>> STREAM ACTION NEWS JAX LIVE <<<
[DOWNLOAD: Free Action News Jax app for alerts as news breaks]
The district's policy handbook review committee went over the change along with a list of other curriculum changes during its meeting on Wednesday, which included changes to how sex education is taught in schools.
One of the board members brought up a concern over how exactly health classes would be split up, should the policy change end up getting approved. It was over the new policy not mentioning, specifically, how students who identify as male, female or nonbinary would be placed between health classes.
'How are we looking at whether female will be comfortable with a male saying 'hey I'm a female,' and vice versa?' the board member asked.
Superintendent Dr. Christopher Bernier took the question, saying, firstly, that classes would be split for students by the gender assigned to them at birth, lining up with the Florida law allowing health classes to be taught by gender.
He added any parents uncomfortable with the changing of classes would have the chance to opt-out. The school board said parents would be made aware of any changes to their student's health classes both with a physical paper and electronically.
Last month, Action News Jax told you about the school board's consideration of changing the way sex education is taught in schools, which was also included in the policy changes brought up in Wednesday's meeting. Board members shared concerns they received from parents that the policy sets abstinence, or saving sex until marriage, as a standard for the district, which is already the standard in Florida, but doesn't mention teaching about ways to prevent pregnancies.
'It has been scaled back, limited information that is provided on contraceptives. We don't particularly talk about condoms like we have in the past,' one of the district officials said in response to the concerns.
It's worth noting the policy surrounding sex education changes does mention it will teach students about 'ways to control the spread' of sexually transmitted diseases, like AIDS. The policy also would reserve education on STDs for students in grades 6-12.
The school board still needs to make a final approval of these changes before they can happen. The next chance of this happening is in the next school board meeting, which is set for April 1st.
[SIGN UP: Action News Jax Daily Headlines Newsletter]
Click here to download the free Action News Jax news and weather apps, click here to download the Action News Jax Now app for your smart TV and click here to stream Action News Jax live.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion
The HIV Diagnostics Companies Quadrant report offers an in-depth analysis of the global HIV diagnostics market, assessing over 100 companies and highlighting the Top 14 leaders. Market expansion is driven by rising HIV/AIDS prevalence, point-of-care technological advancements, and awareness campaigns. However, high costs and skilled technician shortages hinder growth. North America leads in market dominance due to its HIV/AIDS prevalence and advanced technologies, while Asia Pacific is projected to grow fastest. Key players like Abbott, Siemens Healthineers, and Thermo Fisher Scientific employ strategies like acquisitions and innovations to maintain strong market positions amid evolving trends. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "HIV Diagnostics - Company Evaluation Report, 2025" report has been added to HIV Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for HIV Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 100 companies, of which the Top 14 HIV Diagnostics Companies were categorized and recognized as the quadrant growth can be attributed to the rising prevalence of HIV/AIDS, the advantages offered by point-of-care instruments & kits, and increasing initiatives for HIV awareness campaigns. However, the high cost of NATs, operational barriers, and the shortage of skilled laboratory technicians are key factors restraining the market growth. The high growth potential of emerging economies and the trend of self-testing are expected to provide lucrative opportunities for market players during the forecast HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominated the global market in 2023. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North the Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this Players:Key players in this market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland). These players adopt various strategies, such as product launches, expansions, acquisitions, and collaborations, to excel in this (US)Abbott is a leading player in the HIV diagnostics market, known for its impactful Company Product Portfolio that includes FDA- and CE-approved products. The company's strong Company Market Share in the U.S. is complemented by its strategic focus on expanding its presence in emerging markets through varied Company Positioning strategies. By leveraging inorganic growth strategies, such as collaborations and acquisitions, Abbott aims to bolster its Company Healthineers AG (Germany)Siemens Healthineers is a cornerstone in the HIV diagnostics sphere, providing a broad array of medical solutions. Their focus on organic strategies and innovation has allowed them to maintain a competitive Company Positioning. With a significant presence in Europe, America, and emerging markets, they continue to excel in Company Market Share by offering innovative products that meet health sector Fisher Scientific (US)With a comprehensive Company Product Portfolio that spans PCR-based assays and immunoassays, Thermo Fisher Scientific remains a leader. Their strategies focus on regulatory approvals and strategic acquisitions to enhance their Company Market Share. Through collaboration with healthcare organizations, they aim to boost early HIV detection and improve global health access, effectively securing their Company Positioning and Company Ranking in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Prevalence of Hiv/Aids3.2.1.2 Increasing Number of Blood Transfusions & Blood Donations3.2.1.3 Advantages Offered by Poc Diagnostic Kits & Instruments3.2.1.4 Increasing Initiatives for Hiv Awareness Campaigns3.2.2 Restraints3.2.2.1 High Cost of Nats3.2.3 Opportunities3.2.3.1 High Growth Potential of Emerging Economies3.2.3.2 Trend of Self-Testing and Growing Preference for At-Home Diagnostic Kits3.2.4 Challenges3.2.4.1 Operational Barriers and Shortage of Skilled Laboratory Technicians3.3 Trends/Disruptions Impacting Customers' Businesses3.4 Value Chain Analysis3.5 Supply Chain Analysis3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Elisa3.7.2 Complementary Technologies3.7.2.1 Western Blot Tests3.7.3 Adjacent Technologies3.7.3.1 Pcr3.8 Patent Analysis3.9 Key Conferences & Events, 2025-20263.10 Porter's Five Forces Analysis3.10.1 Threat of New Entrants3.10.2 Threat of Substitutes3.10.3 Bargaining Power of Buyers3.10.4 Bargaining Power of Suppliers3.10.5 Intensity of Competitive Rivalry3.11 Impact of Ai/Generative Ai on Hiv Diagnostics Market3.11.1 Market Potential of Ai in Hiv Diagnostics3.11.2 Ai Use Cases3.11.3 Company Implementation of Ai3.11.4 Future of Ai/Generative Ai4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Hiv Diagnostics Market4.3 Revenue Analysis, 2021-20234.4 Market Share Analysis, 20234.4.1 Ranking of Key Market Players4.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Product Footprint4.5.5.4 End-User Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Smes4.7 Company Valuation & Financial Metrics4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product/Service Launches & Approvals4.9.2 Product Launches & Approvals4.9.3 Deals4.9.4 Expansions4.9.5 Other Developments5 Company Profiles Abbott Siemens Healthineers Grifols, S.A. Danaher Corporation Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd. Biomerieux Hologic, Inc. Qiagen Bd Trinity Biotech Orasure Technologies, Inc. Biosynex Sa Wondfo Getein Biotech, Inc. Meril Life Sciences Pvt. Ltd. Accubiotech Co., Ltd. Biolytical Laboratories Inc. Bio Lab Diagnostics (I) Private Limited Alpine Biomedicals Pvt Ltd. Molbio Diagnostics Pvt. Ltd. Fortress Diagnostics Advacare Pharma (Accuquik) Adaltis S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WebMD
5 days ago
- WebMD
Breakthroughs in HIV
It's been over 40 years since the emergence of HIV. It's killed hundreds of thousands of Americans, and millions of people globally. Those numbers would be even higher without medical breakthroughs. Let's talk about some of them. In 1996, Highly Active Antiretroviral Therapy (HAART) was developed. It suppresses the virus from replicating and attacking your immune system, which lowers your viral load and increases the CD4 (white blood cells that fight infections for your immune system). That reduces your risk of opportunistic infections and extends your life expectancy. The decrease in viral load makes HIV less transmissible and helps reconstitute your immune system, but it took a while before it was known by how much This was a major breakthrough in HIV treatment and prevention. But it was hardly the first. Perhaps the first big break came in 1983, when scientists isolated the virus that pinpointed the cause of AIDS. This revolutionized the understanding of AIDS — where it was, how it works, and how to combat it. Then in 1985, the first HIV blood test was licensed. This was a breakthrough of sorts, because it allowed the virus to be detected before it was too late. But there was still no treatment. That came in 1987 when AZT was developed. AZT was the first antiretroviral treatment for HIV-AIDS. It helped and prevented mother-to-child transmission of the virus. But it had serious side effects. I've heard horrible stories from AZT survivors, but it was all that was available at the 1996, when HAART changed everything. By 1997, it was the standard of care for new HIV cases. In 2012, it was discovered that providing HIV medication to HIV-negative people at high risk for the virus could prevent transmission, with an incredible success rate. This is called pre-exposure prophylaxis or PrEP. It was meant to be another amazing breakthrough in science. For the first time, there was a proven method of preventing HIV transmission. The implications included ending transmission of HIV, and ending the HIV-AIDS epidemic. But PrEP hasn't been widely accepted by the public, mostly due to stigma associated with HIV and LGBTQ people. So we're yet to achieve those goals. The year 2016 changed my life more than any other. I was at a conference in Florida where Bruce Richman spoke about U=U. It played a huge role in my decision to become an HIV advocate. I've been an ambassador for U=U ever since. What is U=U? Undetectable equals Untransmittable means that when you take HIV medication as prescribed, you can achieve an undetectable viral load. This means there's not enough virus in your blood to be counted. What happens to the virus? Small amounts of it can survive but remain harmlessly dormant in your body, in small amounts known as reservoirs. The virus can't be transmitted sexually or mother to child. People who live with HIV can safely have children with no risk of transmission to their partner or baby. This revelation was monumental and it's changed lives. It was a breakthrough in understanding. In 2021, there came the first long-acting injectable. It was a breakthrough for those who struggled with pill fatigue or forgetfulness. Pill fatigue is a common problem, especially because there's also stigma associated with simply taking meds for HIV. I remember learning about injectable HIV medication at a conference called CROI (Conference on Retroviruses and Opportunistic Infections). It's a scientific event that attracts leading experts who discuss research and findings for collective understanding. I've attended the conference twice as a community liaison and learned so much about HIV research and the experts doing it. I learned about the potential for longer acting treatments, and about research exploring different methods of delivery, from injectable treatments to the possibility of implants. I can tell you that even a few years ago, research for a cure of HIV-AIDS was getting really exciting. I truly believe we're close to finding a cure. Now is not the time to kill funding dedicated to this research. I've talked about a lot of breakthroughs in HIV. This year, that list of breakthroughs adds another big advancement. In 2025 the FDA approved a drug that can be injected twice yearly, once every 6 months. It can also be used as PrEP, which has also been approved. That's incredible! You don't have to remember to take meds every day, carry meds with you, or be seen taking them. I hold on to hope that one day one of these breakthroughs will change public perception of HIV. There's no reason to fear this virus as long as you have access to the medicine. The stigma of HIV is antiquated. It's based on a mysterious disease that was a certain death sentence and only affects gay men But none of this is true anymore. HIV is no longer the deadly disease it once was. With incredible advancements, there's no excuse for fear or stigma to exist. HIV today is nothing more than a chronic condition that's easily managed, and only getting better with time. I believe we're close to a cure. I just learned that researchers have found a way to awaken dormant HIV cells. I find that extremely exciting and wonder if it could lead to a cure. If dormant cells can be awakened, then targeted and killed, that could be a cure. It's so exciting that we're getting closer, so it's no time for defunding HIV research and prevention efforts.
Business Wire
5 days ago
- Business Wire
Feinstein Institutes' Dr. Douglas F. Nixon Named Fellow of the Infectious Disease Society of America
BUSINESS WIRE)--For his contributions to immunovirology research, Douglas F. Nixon, MD, PhD, director of Northwell Health's Institute of Translational Research at the Feinstein Institutes for Medical Research, has been named a Fellow of the Infectious Diseases Society of America (IDSA). For over 30 years, Dr. Nixon has been a leading figure in immunovirology research, spanning clinical research, human immunology, basic virology and molecular biology. A pioneer in the study of human endogenous retroviruses (HERVs) – often called 'junk DNA' or 'dark genome' that does not code for genes – Dr. Nixon investigates their influence on neuroimmunological, neurodevelopmental and neurodegenerative conditions. As the leader of the Institute of Translational Research, Dr. Nixon heads a team whose research aims to accelerate the development of treatments for a variety of diseases, including Alzheimer's disease, cancer, HIV/AIDS, other viral infections and mental health disorders. 'I am honored to be elected a Fellow of the Infectious Diseases Society of America. This recognition is a testament to the collaborative spirit and dedication of my colleagues and mentors who have inspired and supported me throughout my career,' said Dr. Nixon. 'I am eager to contribute further to the critical mission of the society, advancing research and clinical care in infectious diseases for the benefit of patients worldwide.' Dr. Nixon has built a distinguished career in immunology and virology, earning degrees from University College London, the University of London, and the University of Oxford. His work spans biotech, academia and research institutions, including Rockefeller University, the Gladstone Institute, UCSF, George Washington University, Weill Cornell, and now at the Feinstein Institutes. With over 330 publications and continuous National Institutes of Health (NIH) funding for 25 years, Dr. Nixon's accomplishments include the Elizabeth Glaser Scientist Award, an NIH R37 merit award and fellowships in the American Society for Clinical Investigation, National Academy of Inventors and American Academy of Microbiology. He also led NIH initiatives focused on AIDS vaccine research and HIV cure research, which has earned him widespread recognition. 'Dr. Nixon's election as a Fellow of the Infectious Diseases Society of America is a high honor that reflects his exceptional scientific leadership,' said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'His groundbreaking work in ancient DNA is transforming how we understand the origins and evolution of infectious diseases and is paving the way toward more effective treatments.' The IDSA is a global community of over 13,000 clinicians, scientists and public health experts who tackle infectious disease challenges ranging from microscopic microbes to widespread outbreaks. Driven by science, a commitment to health equity and a spirit of inquiry, IDSA members work to protect individual, community and global health by advancing the treatment and prevention of infectious diseases. Fellowship in IDSA is one of the highest honors in the field of infectious diseases, recognizing distinguished clinicians and scientists from the U.S. and around the world whose contributions continue to move the field forward. This year, the IDSA is welcoming 167 Fellows during its annual meeting in the fall. Dr. Nixon recently published research in Trends in Immunology that showed the five senses – sight, smell, taste, touch and sound – play a key role in the immune system. He calls this 'shared immunity,' and explains that the body can communicate and share immune benefits with others, even across generations. This research significantly expands the understanding of the complex interplay between the senses, the immune system and the environment though genetics and generational evolution, offering potential new directions for future research and the development of innovative therapeutic strategies to enhance immune defenses. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
